<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00578266</url>
  </required_header>
  <id_info>
    <org_study_id>06-006216</org_study_id>
    <nct_id>NCT00578266</nct_id>
  </id_info>
  <brief_title>Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia</brief_title>
  <official_title>Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia, Using Matched Unrelated Donors and Mismatched Related Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For patients with severe aplastic anemia (SAA) who have failed to respond to&#xD;
      immunosuppressive therapy and lack an HLA identical family member, our objectives are to make&#xD;
      an initial assessment of the safety and efficacy of allogenic stem cell transplantation from&#xD;
      either a matched unrelated donor or a mismatched reacted donor using the conditioning regimen&#xD;
      of Cytoxan, reduced total body irradiation (TBI) and Campath IH. The principle measures of&#xD;
      safety and efficacy will be :&#xD;
&#xD;
        1. Patient survival probability at 100 days, 1 year and 2 years.&#xD;
&#xD;
        2. Incidence of graft versus host disease (GVHD), as well as incidence of acute GVHD and&#xD;
           chronic GVHD within 6 months and 2 years.&#xD;
&#xD;
        3. Engraftment at 6 months, 1 year and 2 years&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this trial is to make an initial assessment for this new treatment regimen&#xD;
      and to show it is equal or superior to the current standard practice. With this initial&#xD;
      assessment be hope to gain information suggesting further study of this regimen or&#xD;
      discontinuation of this regimen before exposing large numbers of patients to this new&#xD;
      treatment option. We also will gain experience with this new regimen giving insights as to&#xD;
      possible modifications in dosing and monitoring and selection of patients for future&#xD;
      treatment in case of positive results. For this initial study we plan to enroll up to 24&#xD;
      patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">August 16, 2016</completion_date>
  <primary_completion_date type="Actual">August 16, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1. Engraftment at 6 months, 1 year and 2 years 2.Incidence of graft versus host disease (GVHD), as well as incidence of acute GVHD and chronic GVHD within 6 months and 2 years</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient survival probability at 100 days, 1 year and 2 years.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Anemia, Aplastic</condition>
  <arm_group>
    <arm_group_label>No Arms</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide,Campath IH and TBI</intervention_name>
    <description>DAY 5 TREATMENT&#xD;
6 5 CYTOXAN 50 mg/kg WITH MESNA&#xD;
5 CYTOXAN 50 mg/kg WITH MESNA;&#xD;
4 CYTOXAN 50 mg/kgWITH MESNA; CAMPATH 3-10 mg&#xD;
3 CYTOXAN 50 mg/kg WITH MESNA; CAMPATH;&#xD;
2 TBI; CAMPATH; TACROLIMUS&#xD;
1 TBI (second fraction); CAMPATH (am) 0 STEM CELL INFUSION (pm)</description>
    <arm_group_label>No Arms</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of SAA based on bone marrow aspirate and biopsy results. Failure to respond&#xD;
             to immunosuppressive therapy and/or lack of an HLA identical family member.&#xD;
&#xD;
          -  A 10/10 or 9/10 HLA matched unrelated donor or a 9/10 matched related donor available&#xD;
             after high resolution typing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with Aplastic anemia and active infection must be treated to maximally&#xD;
             resolve this problem before beginning the conditioning regimen.&#xD;
&#xD;
          -  HIV seropositive patients&#xD;
&#xD;
          -  Patients who have clonal cytogenetic abnormalities or a myelodysplastic syndrome.&#xD;
&#xD;
          -  Patient greater than 60 years of age.&#xD;
&#xD;
          -  Women who are pregnant or nursing.&#xD;
&#xD;
          -  Patients with active hepatitis&#xD;
&#xD;
          -  Patients with severe cardiac dysfunction defined as shortening fraction &lt;25%.&#xD;
&#xD;
          -  Patients with severe renal dysfunction defined as creatinine clearance&#xD;
             &lt;40ml/mim/1.73m2.&#xD;
&#xD;
          -  Patient with severe pulmonary dysfunction with FEV1, FVC and DLCO 40% of predicted or&#xD;
             3 SD below normal.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shakila P. Khan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>December 17, 2007</study_first_submitted>
  <study_first_submitted_qc>December 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2007</study_first_posted>
  <last_update_submitted>March 23, 2017</last_update_submitted>
  <last_update_submitted_qc>March 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Shakila Khan</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Severe Aplastic Anemia (SAA)</keyword>
  <keyword>Transplant for Severe Aplastic Anemia (SAA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

